Our revenue-generating partnered programmes validate the strength of our Arestat® technology, its value to partners and our leadership position in drug delivery and formulation innovation.   

Partnerships are key to our near-term revenue generation and long-term value for shareholders.

Partnership portfolio highlights

  • Arestat® enhanced biosimilar product, AT220, is under a worldwide licensing agreement *
  • Sanofi’s programme, SAR447537, formerly INBRX-101 (AT292), acquired from Inhibrx, incorporates Arestat® technology under a revenue-generating license *
  • Arestat®-enhanced AT351 is under an exclusive milestone and royalty-bearing licensing agreement with a subsidiary of one of the world’s largest independent chemicals marketing companie
  • Growing portfolio of pre-license technology partnerships, offering upside potential from partnering

* Global royalty rights to AT220 and all potential milestone and technology access fees related to AT292 were sold to Ligand Pharmaceuticals in September 2025.

How we work with partners

We collaborate with companies under a technology licensing model to develop superior versions of their developmental and commercial high-value complex biological products.

Our partners pay technology development fees and upon completion, have the option to enter into a license agreement for rights to access the intellectual property and further develop and commercialise the novel formulation.  These licenses typically involve both milestone and royalty payments.

Applying our Arestat® technology

Our proprietary Arestat® technology can be applied to high-value biologics, including biosimilars, novel biologics, peptides and vaccines, as well as future potential applications such as oral delivery, mRNA and cell and gene therapies.

Products can be at any stage in development from early phase clinical development through to commercialised. The most successful candidates are complex specialty products used for the treatment of chronic or life-threatening diseases with a high cost, requiring special storage, handling or complex administration where we can leverage our Arestat® technology to improve and differentiate these characteristics.